Peritransplant Treg-Based Immunomodulation to Improve VCA Outcomes

Abstract

We have undertaken studies of how Treg cells, or pharmacologic modulators of Treg function called HDAC inhibitors, may be used to enhance outcomes in VCA recipients, using murine models of orthotopic limb transplantation. Using this model, we have shown that expansion of Tregs can be used to significantly prolong orthotopic limb allograft survival. In addition, we have shown that Treg infusion or use of an HDAC inhibitor can be used to promote long-term orthotopic VCA survival.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2019
Accession Number
AD1093209

Entities

People

  • Wayne W Hancock

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Allografts
  • Bone Marrow
  • Cells
  • Department Of Defense
  • Enzyme Inhibitors
  • Health Services
  • Immunomodulation
  • Infusions
  • Inhibitors
  • Lymphatic System
  • Lymphocytes
  • Medical Personnel
  • Professional Development
  • Survival
  • Therapy
  • Transplantation
  • Transplants

Fields of Study

  • Biology
  • Medicine

Readers

  • Molecular and Cellular Biology
  • Neuroscience
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech